Sigma Planning Corp In8 Bio, Inc. Transaction History

Sigma Planning Corp

$3.02 Billion
Q1 2025

A detailed history of Sigma Planning Corp transactions in In8 Bio, Inc. stock. As of the latest transaction made, Sigma Planning Corp holds 700,680 shares of INAB stock, worth $84,081. This represents 0.0% of its overall portfolio holdings.

Number of Shares

700,680

Previous 1,041,380 32.72%

Holding current value

$84,081

Previous $281,000 57.65%

% of portfolio

0.0%

Previous 0.01%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 01, 2025	SELL	$0.17 - $0.35 $57,919 - $119,244	-340,700 Reduced 32.72%	700,680 $119,000
Q4 2024 Feb 03, 2025	BUY	$0.23 - $0.48 $43,723 - $91,248	190,100 Added 22.33%	1,041,380 $281,000
Q3 2024 Nov 01, 2024	BUY	$0.27 - $0.88 $67,932 - $221,408	251,600 Added 41.96%	851,280 $229,000
Q2 2024 Aug 05, 2024	BUY	$0.85 - $1.68 $71,910 - $142,128	84,600 Added 16.42%	599,680 $509,000
Q1 2024 May 01, 2024	BUY	$0.95 - $1.69 $363,707 - $647,016	382,850 Added 289.53%	515,080 $607,000
Q4 2023 Feb 01, 2024	SELL	$0.69 - $2.34 $105,445 - $357,598	-152,820 Reduced 53.61%	132,230 $182,000
Q3 2023 Nov 06, 2023	BUY	$0.92 - $1.74 $5,198 - $9,831	5,650 Added 2.02%	285,050 $296,000
Q2 2023 Aug 01, 2023	BUY	$1.05 - $3.24 $79,275 - $244,620	75,500 Added 37.03%	279,400 $430,000
Q1 2023 May 05, 2023	BUY	$1.17 - $2.83 $122,557 - $296,442	104,750 Added 105.65%	203,900 $265,000
Q4 2022 Jan 24, 2023	BUY	$1.39 - $2.47 $556 - $988	400 Added 0.41%	99,150 $0
Q3 2022 Nov 10, 2022	BUY	$1.77 - $2.89 $1,770 - $2,890	1,000 Added 1.02%	98,750 $199,000
Q1 2022 Apr 20, 2022	BUY	$2.76 - $4.6 $190,853 - $318,090	69,150 Added 241.78%	97,750 $326,000
Q4 2021 Feb 02, 2022	BUY	$4.39 - $8.55 $125,553 - $244,530	28,600 New	28,600 $126,000

Others Institutions Holding INAB

# of Institutions

Shares Held

21.7M

Call Options Held

Put Options Held

View Full List

About IN8BIO, INC.

Ticker INAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,502,200
Market Cap $2.94M
Description
IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of...

More about INAB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Sigma Planning Corp, based on Form 13F filings with the SEC.

News

Stay updated on Sigma Planning Corp with notifications on news.

Account

Sigma Planning Corp In8 Bio, Inc. Transaction History